Dose-escalation, PK- and Safety Study With Single Agent CetuGEX in Patients With EGFR Positive Locally Advanced and/or Metastatic Cancer.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Tomuzotuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Glycotope
- 02 Apr 2014 Tolerability and efficacy data presented, according to a Glycotope media release.
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jul 2013 Promising first-in-man data were presented at ASCO 2013, according to a Glycotope media release.